Department of Medicine, Division of Cardiovascular Medicine, Medical College of Wisconsin, Hub for Collaborative Medicine, 5th Floor A5743, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA.
Department of Pharmacology, Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Cardiovasc Diabetol. 2019 Nov 9;18(1):148. doi: 10.1186/s12933-019-0956-4.
Excessive reactive oxygen species from endothelial mitochondria in type 2 diabetes individuals (T2DM) may occur through multiple related mechanisms, including production of mitochondrial reactive oxygen species (mtROS), inner mitochondrial membrane (Δψ) hyperpolarization, changes in mitochondrial mass and membrane composition, and fission of the mitochondrial networks. Inner mitochondrial membrane proteins uncoupling protein-2 (UCP2) and prohibitin (PHB) can favorably impact mtROS and mitochondrial membrane potential (Δψ). Circulating levels of UCP2 and PHB could potentially serve as biomarker surrogates for vascular health in patients with and without T2DM.
Plasma samples and data from a total of 107 individuals with (N = 52) and without T2DM (N = 55) were included in this study. Brachial artery flow mediated dilation (FMD) was measured by ultrasound. ELISA was performed to measure serum concentrations of PHB1 and UCP2. Mitochondrial membrane potential was measured from isolated leukocytes using JC-1 dye.
Serum UCP2 levels were significantly lower in T2DM subjects compared to control subjects (3.01 ± 0.34 vs. 4.11 ± 0.41 ng/mL, P = 0.04). There were no significant differences in levels of serum PHB. UCP2 levels significantly and positively correlated with FMDmm (r = 0.30, P = 0.03) in T2DM subjects only and remained significant after multivariable adjustment. Within T2DM subjects, serum PHB levels were significantly and negatively correlated with UCP2 levels (ρ = - 0.35, P = 0.03).
Circulating UCP2 levels are lower in T2DM patients and correlate with endothelium-dependent vasodilation in conduit vessels. UCP2 could be biomarker surrogate for overall vascular health in patients with T2DM and merits additional investigation.
2 型糖尿病个体(T2DM)内皮线粒体产生的过多活性氧可能通过多种相关机制发生,包括线粒体活性氧(mtROS)的产生、线粒体内膜(Δψ)超极化、线粒体质量和膜组成的变化以及线粒体网络的分裂。线粒体内膜蛋白解偶联蛋白 2(UCP2)和抑制素(PHB)可以有利地影响 mtROS 和线粒体膜电位(Δψ)。循环 UCP2 和 PHB 水平可能作为 T2DM 患者和非 T2DM 患者血管健康的生物标志物替代物。
本研究共纳入 107 名个体的血浆样本和数据,其中 T2DM 患者(N=52)和非 T2DM 患者(N=55)。肱动脉血流介导的扩张(FMD)通过超声测量。酶联免疫吸附试验(ELISA)用于测量血清 PHB1 和 UCP2 浓度。使用 JC-1 染料从分离的白细胞中测量线粒体膜电位。
与对照组相比,T2DM 患者的血清 UCP2 水平显著降低(3.01±0.34 vs. 4.11±0.41 ng/mL,P=0.04)。血清 PHB 水平无显著差异。UCP2 水平仅在 T2DM 患者中与 FMDmm 呈显著正相关(r=0.30,P=0.03),且在多变量调整后仍有意义。在 T2DM 患者中,血清 PHB 水平与 UCP2 水平呈显著负相关(ρ=-0.35,P=0.03)。
T2DM 患者的循环 UCP2 水平较低,与导血管内皮依赖性血管舒张相关。UCP2 可能是 T2DM 患者整体血管健康的生物标志物替代物,值得进一步研究。